Niklas Landberg, a researcher at Lund University and hematologist at Skåne University Hospital, has been awarded the Skåne University Hospital and Medical Faculty prize for his work on acute myeloid leukemia (AML).
His research focuses on identifying new molecular targets to improve clinical outcomes for patients facing this aggressive blood cancer.
Distinguishing acute myeloid leukemia from other blood cancers is a major difficulty in oncology. Unlike acute lymphoblastic leukemia (ALL), where immunotherapy has demonstrated clear clinical efficacy, AML has historically proven more resistant to such interventions. Landberg’s work seeks to bridge this gap by mapping the immunological mechanisms that could serve as a foundation for novel, targeted therapies.
“Our findings have led us into studies of immunological mechanisms that we now hope to develop further as a basis for new therapies,” Landberg told Läkartidningen. He also said that his team is investigating the transition process from clonal hematopoiesis—a condition where blood stem cells acquire mutations—to overt leukemia, aiming to determine if these early-stage processes can be therapeutically intercepted.
- Clonal Hematopoiesis: This refers to the presence of mutated blood stem cells in individuals who do not yet have cancer; understanding why some cases progress to AML is key to future preventative care.
- Risk Stratification: By better identifying which patients are at high risk, clinicians hope to reduce the burden of unnecessary follow-up procedures for those with lower-risk profiles.
The prize committee recognized Landberg for identifying new “target molecules” within the disease mechanisms of AML. In oncology, a target molecule is typically a protein or genetic sequence that is overexpressed or mutated in cancer cells. By inhibiting or modulating these specific targets, researchers aim to disrupt the signaling pathways that allow leukemic cells to proliferate unchecked.
The current research trajectory aims to move these findings from the laboratory bench to clinical trials. “For our findings in AML, it would be fantastic if they could be translated into new effective immunotherapies in the future,” Landberg explained to Läkartidningen. Regarding the management of clonal hematopoiesis, he emphasized the importance of preventing progression to full-blown leukemia, noting that improved risk stratification would allow for more efficient patient management.
| Research Focus | Clinical Objective |
|---|---|
| Immunological Mechanisms | Development of targeted AML immunotherapy |
| Clonal Hematopoiesis | Prevention of progression to acute leukemia |
| Risk Stratification | Reduction of unnecessary patient follow-up |
Patients currently undergoing AML protocols must adhere to the regimen prescribed by their hematology-oncology team. Contraindications for existing AML therapies often include severe comorbidities, such as end-stage organ failure or specific active infections, which may preclude intensive chemotherapy or stem cell transplantation.
Individuals experiencing symptoms such as unexplained fatigue, recurring fevers, easy bruising, or persistent infections should consult a primary care physician immediately. These symptoms warrant a complete blood count (CBC) to screen for hematological abnormalities. If abnormalities are identified, referral to a hematologist for bone marrow biopsy and genetic testing is the standard of care for definitive diagnosis.
The shift toward personalized hematology requires rigorous validation in multi-center, double-blind, placebo-controlled trials—the gold standard for determining if a new treatment is truly effective and safe.
The fundamental question remains: can the transition from pre-leukemic clonal hematopoiesis be stalled before the emergence of clinical symptoms? "Within clonal hematopoiesis, I hope that we will know more about how progress to leukemia can be prevented," Landberg stated in his correspondence with Läkartidningen.
